• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

头孢地尔在 ICU 患者治疗鲍曼不动杆菌和其他碳青霉烯类耐药革兰氏阴性菌感染中的应用。

Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients.

机构信息

Infectious Diseases Azienda Ospedaliera Universitaria Pisana Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Department of Anaesthesia and Critical Care Medicine, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.

出版信息

Clin Infect Dis. 2021 Jun 1;72(11):2021-2024. doi: 10.1093/cid/ciaa1410.

DOI:10.1093/cid/ciaa1410
PMID:32941593
Abstract

Ten critically ill patients with either bacteremia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, or New Delhi metallo-β-lactamase-producing Klebsiella pneumoniae received cefiderocol. All strains had minimum inhibitory concentration ≤2 μg/mL. Thirty-day clinical success and survival rates were 70% and 90%, respectively. Two patients had a microbiological failure. Future prospective studies are warranted.

摘要

十名患有血流感染或呼吸机相关性肺炎的重症患者，其感染的细菌分别为耐碳青霉烯鲍曼不动杆菌、嗜麦芽窄食单胞菌或产新德里金属β-内酰胺酶肺炎克雷伯菌，这些患者接受了头孢地尔。所有菌株的最低抑菌浓度均≤2μg/mL。30 天临床成功率和生存率分别为 70%和 90%。两名患者发生微生物学失败。需要进行未来的前瞻性研究。

相似文献

1
Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients.头孢地尔在 ICU 患者治疗鲍曼不动杆菌和其他碳青霉烯类耐药革兰氏阴性菌感染中的应用。
Clin Infect Dis. 2021 Jun 1;72(11):2021-2024. doi: 10.1093/cid/ciaa1410.
2
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
3
In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).头孢地尔罗的体外活性，一种铁载体头孢菌素，针对最近收集的临床相关碳青霉烯类药物不敏感的革兰氏阴性杆菌，包括丝氨酸碳青霉烯酶和金属β-内酰胺酶产生的分离株（SIDERO-WT-2014 研究）。
Int J Antimicrob Agents. 2019 Feb;53(2):177-184. doi: 10.1016/j.ijantimicag.2018.10.007. Epub 2018 Oct 26.
4
Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis.全球肠杆菌科、铜绿假单胞菌、鲍曼不动杆菌和嗜麦芽寡养单胞菌对头孢地尔罗耐药的流行情况：系统评价和荟萃分析。
Clin Microbiol Infect. 2024 Feb;30(2):178-188. doi: 10.1016/j.cmi.2023.08.029. Epub 2023 Sep 4.
5
Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.头孢地尔在碳青霉烯类耐药鲍曼不动杆菌感染管理中的前瞻性作用：证据回顾。
Int J Antimicrob Agents. 2023 Aug;62(2):106882. doi: 10.1016/j.ijantimicag.2023.106882. Epub 2023 Jun 8.
6
Resistotyping, phenotyping and genotyping of New Delhi metallo-β-lactamase (NDM) among Gram-negative bacilli from Iranian patients.伊朗患者革兰氏阴性杆菌中新型德里金属β-内酰胺酶（NDM）的耐药分型、表型分析及基因分型
J Med Microbiol. 2017 Apr;66(4):402-411. doi: 10.1099/jmm.0.000444. Epub 2017 Apr 21.
7
Role of β-lactamase inhibitors on cefiderocol activity against carbapenem-resistant Acinetobacter species.β-内酰胺酶抑制剂对头孢地尔抗碳青霉烯类耐药不动杆菌属细菌活性的作用
Int J Antimicrob Agents. 2023 Jan;61(1):106700. doi: 10.1016/j.ijantimicag.2022.106700. Epub 2022 Dec 5.
8
In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.在加拿大重症监护病房中分离的革兰氏阴性杆菌的体外活性研究：新型铁载体头孢菌素头孢地尔。
Diagn Microbiol Infect Dis. 2020 May;97(1):115012. doi: 10.1016/j.diagmicrobio.2020.115012. Epub 2020 Feb 4.
9
Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.头孢地尔罗对多重耐药肠杆菌科、鲍曼不动杆菌、铜绿假单胞菌和嗜麦芽窄食单胞菌高危克隆的活性。
J Antimicrob Chemother. 2020 Jul 1;75(7):1840-1849. doi: 10.1093/jac/dkaa117.
10
Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.分析 ICU 患者下呼吸道感染的鲍曼不动杆菌分离株的表型和分子特征。
Microb Pathog. 2019 Mar;128:75-81. doi: 10.1016/j.micpath.2018.12.023. Epub 2018 Dec 15.

引用本文的文献

1
Real-world effectiveness and safety of cefiderocol in critically ill patients with MDR Gram-negative infections: Results from a retrospective study.头孢地尔在多重耐药革兰阴性菌感染重症患者中的真实世界有效性和安全性：一项回顾性研究的结果
Biomed Rep. 2025 Jul 22;23(4):156. doi: 10.3892/br.2025.2034. eCollection 2025 Oct.
2
Case Commentary: Overcoming intrinsic resistance-the successful use of aztreonam and avibactam for meningitis.病例评论：克服内在耐药性——氨曲南和阿维巴坦成功用于治疗脑膜炎
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0064025. doi: 10.1128/aac.00640-25. Epub 2025 Jul 9.
3
Real-life impact of cefiderocol in carbapenem-resistant Acinetobacter baumannii infections (CRAb): a narrative review.
头孢地尔对耐碳青霉烯鲍曼不动杆菌感染（CRAB）的实际影响：一项叙述性综述。
Eur J Clin Pharmacol. 2025 Jun 12. doi: 10.1007/s00228-025-03866-y.
4
Newly developed antibiotics against multidrug-resistant and carbapenem-resistant Gram-negative bacteria: action and resistance mechanisms.针对多重耐药和碳青霉烯耐药革兰氏阴性菌的新型抗生素：作用机制与耐药机制
Arch Microbiol. 2025 Apr 2;207(5):110. doi: 10.1007/s00203-025-04298-z.
5
Phenotypic and Molecular Characterization of Pyomelanin-Producing ST2;ST1816/ST195 Causing the First European Nosocomial Outbreak.引起首例欧洲医院感染暴发的产脓黑素的ST2；ST1816/ST195的表型和分子特征
Microorganisms. 2025 Feb 22;13(3):493. doi: 10.3390/microorganisms13030493.
6
Epidemiological and genomic analysis of strains from retailed raw meat.零售生肉菌株的流行病学和基因组分析。
Heliyon. 2024 Dec 25;11(1):e41487. doi: 10.1016/j.heliyon.2024.e41487. eCollection 2025 Jan 15.
7
Drug-resistant bacteria in the critically ill: patterns and mechanisms of resistance and potential remedies.危重症患者中的耐药菌：耐药模式、机制及潜在治疗方法
Front Antibiot. 2023 Jun 30;2:1145190. doi: 10.3389/frabi.2023.1145190. eCollection 2023.
8
Updates on the Activity, Efficacy and Emerging Mechanisms of Resistance to Cefiderocol.头孢地尔的活性、疗效及新出现的耐药机制研究进展
Curr Issues Mol Biol. 2024 Dec 14;46(12):14132-14153. doi: 10.3390/cimb46120846.
9
Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria.头孢地尔治疗产VIM型革兰阴性菌感染
Antibiotics (Basel). 2024 Sep 12;13(9):874. doi: 10.3390/antibiotics13090874.
10
Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant infections.接受头孢地尔治疗碳青霉烯耐药感染患者中头孢地尔异质性耐药的发生率。
JAC Antimicrob Resist. 2024 Sep 9;6(5):dlae146. doi: 10.1093/jacamr/dlae146. eCollection 2024 Oct.